628 Results
Sort By:
Published on August 9, 2022
Research led by Tel Aviv University and the University of Lisbon has identified a small molecule inhibitor which may be a more accessible and effective alternative to anti-PD-1/PD-L1 immunotherapy antibodies already being used to treat a range of cancers. Inhibiting programmed cell death protein 1 (PD1) and the PD-ligand 1…
Published on July 20, 2022
Researchers at the Royal Adelaide Hospital and the University of South Australia have discovered that a dual combination of standard transplant anti-rejection drugs with immunotherapy can eradicate cancer cells in a quarter of transplant patients while also protecting their new organ. “Cancer is a leading cause of death in kidney…
Published on June 23, 2022
New research published in the Journal of Thoracic Oncology Clinical and Research Reports shows that Hummingbird Diagnostics’ blood-based 5-miRNA signature (miRisk) can predict survival in patients with non-small cell lung cancer (NSCLC) with high PD-L1 expression after they have received immunotherapy. The results point to miRisk being able to answer…
Published on June 8, 2022
Libraries of immune cells displaying diverse repertoires of chimeric antigen receptors (CARs) have been developed that can recognize non-self antigens and display antigen-dependent clonal expansion, with the expanded population of tumor-specific effector cells leading to long-lasting antitumor responses in mouse models of epithelial tumors. Over the past decade, substantial progress…
Published on June 1, 2022
A new ultrasound-guided cancer immunotherapy platform developed by MD Anderson Cancer Center scientists has demonstrated it generates systemic antitumor immunity and improves the therapeutic efficacy of immune checkpoint blockade according to a new study published in Nature Nanotechnology. The Microbubble-assisted UltraSound-guided Immunotherapy of Cancer (MUSIC) approach employs nanocomplexes combined with…
Published on May 18, 2022
Researchers are looking to improve immunotherapy for liver cancer or hepatoceulluar carcinoma (HCC). Although immunotherapy has become the standard therapeutic method for fighting HCC, its response rate has only been approximately 30% in patients with advanced disease. Now, researchers at Osaka University report they have developed an analytical method that…
Published on May 18, 2022
New longer-term results from the CheckMate 274 trial show that adjuvant immunotherapy with nivolumab after surgery and chemotherapy helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle. This analysis showed that patients treated with immunotherapy…
Published on May 11, 2022
Immunotherapy unleashes the immune system to fight cancer, but it doesn’t work for all patients, and newly reported research may help to explain why. The study, headed by a team at Weill Cornell Medicine, indicates that the genetic program of T lymphocyte immune cells infiltrating malignant tumors, and the developmental…
Published on May 4, 2022
It’s not often that a failed clinical trial leads to a scientific breakthrough. But when patients in the UK started showing adverse side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back through the data…
Published on April 18, 2022
Researchers in the Pelotonia Institute for Immuno-Oncology (PIIO) at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) observed the differences in intratumoral immune responses between male and female cancers of non-reproductive origin. The new study is published in…
Published on April 6, 2022
Harvard researchers have shown that a diet rich in omega-3 fatty acids enhances immunotherapy response in mouse models of bladder cancer, lung cancer, and melanoma. They also revealed that consumption of high levels of omega-6 fatty acids—common in American diets—was associated with a poor response to immunotherapy that could be…
Published on March 30, 2022
The U.S. Food and Drug Administration has approved the use of the anti-lymphocyte-activation gene (LAG)-3 agent relatlimab in combination with the anti-programmed death (PD)-1 drug nivolumab for patients with treatment-naïve advanced melanoma. The approval is based on the results of the Phase II/III RELATIVITY-047 trial published in the New England…
Published on March 30, 2022
Adding the anti-inflammatory medication celecoxib to immunotherapy and standard chemotherapy drugs appears to suppress aggressive bladder tumor growth, according to a proof-of-concept study led by investigators from Cedars-Sinai Medical Center. The findings, made in laboratory mice, were published in Nature Communications. Chemotherapy and immune checkpoint blockade therapy represent the two pillars…
Published on February 17, 2022
Researchers at Wake Forest School of Medicine report that they have found biomarkers that indicate whether a patient will benefit from the use of immune checkpoint inhibitors (ICIs) to treat melanoma. Melanoma is often curable if discovered and treated in its earliest stages, but when the disease progresses it can…
Published on January 26, 2022
One of the main challenges with immunotherapies is the range in their effectiveness. While in some people tumors shrink or even disappear others people have no response at all. Researchers have been trying to understand this disparity for some time. The gut microbiome has emerged as one possible factor. Gut…